未知生产厂商
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine.
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
